FES anticorps (truncated)

N° du produit ABIN2464051

Cet anticorps Souris Monoclonal détecte spécifiquement FES dans WB, ELISA et IHC. Il présente une réactivité envers Humain.

Aperçu rapide pour FES anticorps (truncated) (ABIN2464051)

Antigène: FES (Feline Sarcoma Oncogene (FES))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp FES est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Clone: 2E3G3-2G9G1

Détail du produit anti-FES anticorps

Épitope: truncated

Immunogène: Ni-NTA purified truncated recombinant FES-His expressed in E. Coli strain BL21 (DE3).

Isotype: IgG1

Information d'application

Indications d'application: Western Blot:1:500 - 1:2,000
IHC(P):1:500 - 1:2,000
ELISA:Propose dilution 1:10,000.
Determining optimal working dilutions by titration test.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Stock: -20 °C

Stockage commentaire: FES monoclonal antibody can be stored at -20 °C, stable for one year.

Détails sur FES

Antigène: FES (Feline Sarcoma Oncogene (FES))

Autre désignation: FES

Sujet: FES (feline sarcoma oncogene) and Fer are the only two members of a unique family of cytoplasmic protein tyrosine kinases. FES and Fer contain a central Src homology-2 (SH2) domain and a carboxy-terminal tyrosine kinase catalytic domain. They are structurally distinguished from other members of cytoplasmic protein tyrosine kinase subfamilies by the presence of amino-terminal Fer/CIP4 homology and coiled-coil domains. FES was originally identified as an oncogene from avian and feline retroviruses. Human c-Fes has been implicated in myeloid, vascular endothelial and neuronal cell differentiation. FES has tyrosine-specific protein kinase activity and that activity is required for maintenance of cellular transformation. Mutations may activate the FES kinase and thereby contribute to cancer. However, recent data strongly suggests that the c-FES protein-tyrosine kinase is a tumor suppressor rather than a dominant oncogene in colorectal cancer.

ID gène: 2242

UniProt: P07332

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Signaling Events mediated by VEGFR1 and VEGFR2